Emmanuel G Prestat

I'm a Data Scientist, working in Microbiota based therapeutics

[MaaT Pharma @MaaT_Pharma]

📢 A recent review by Wenjing Hao, Nicolas Stocker , Béatrice Gaugler, Mohamad Mohty and Florent Malard published in the American Journal of Hematology, highlights the persistent challenges of gastrointestinal acute GvHD, one of the most devastating complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT).

🔎 Despite advances in transplant care, patients with steroid- and ruxolitinib-refractory GI-aGvHD still face poor outcomes and very limited therapeutic options, underscoring a critical unmet medical need.

🦠 The review is based on the growing body of evidence, supporting the role of the gut microbiome in transplant outcomes, immune regulation, and GvHD pathophysiology, supporting the investigation of new therapeutic approachess in this setting.

👉 Read the publication here: https://t.co/SosKDIAuUc

@WileyLifeSci @NStockerSAT @Mohty_EBMT @Florent_Malard @AjHematology
#Microbiome #aGvHD #GvHD #alloHSCT #Hematology #CellTherapy #Oncology #UnmetNeed #Cancer

[Emmanuel G Prestat @ManuFrenchy]

@mathladyhazel Neat, just surprised that N is not more abundant considering it's 80% of atmosphere. But I guess it has to do with density...

[Neo4j @neo4j]

We know that creating knowledge graphs from unstructured data can be a headache.

Now? The Neo4j GraphRAG for Python package includes a Knowledge Graph Builder to help you convert your unstructured and structured data.

The result: Organized representations of real-world entities and relationships that power better #AI applications.

Read more about this ⬆️ in the blog and learn how to create them in the #GraphAcademy course "Constructing Knowledge Graphs with Neo4j GraphRAG for Python." https://t.co/PHEB3nm7lJ

#Python
#Neo4j

[MaaT Pharma @MaaT_Pharma]

📰 [#PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease have been selected for oral presentation at American Society of Hematology (@ASH_hematology) Congress 2025.

Key highlights:
✅ Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg®(MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary endpoints (data at Day 56 and 3 months, and duration of response).
✅ Results highlight strong efficacy and indicate a favorable safety profile for Xervyteg® (MaaT013), reinforcing its potential to become the first third-line treatment for patients with gastrointestinal aGvHD unresponsive to current therapies.
✅ Xervyteg®(MaaT013) is currently under regulatory review by the European Medicines Agency (EMA), with a decision anticipated in the second half of 2026.

👉 Read the full press release for more information: https://t.co/GTuEzM3EHk

#ASH2025 #Phase3 #Hematology #Oncology #aGvHD #Xervyteg #Microbiome

[MaaT Pharma @MaaT_Pharma]

📅 Heading to #ASH2025!
Meet MaaT Pharma’s Acting CSO Sheri Simmons & CEO Hervé Affagard in Orlando, Dec 6–9.

We’re also excited for Prof. Florent Malard to present Phase 3 ARES trial results on Xervyteg® (MaaT013) in SR GI-aGvHD patients.

👇 Presentation details below!

@ASH_hematology
#ASH2024 #Hematology #Oncology #Microbiome

[Emmanuel G Prestat @ManuFrenchy]

@mbeisen

[MaaT Pharma @MaaT_Pharma]

🎥 [#Media] À l’occasion de la publication de nos résultats semestriels, notre Directeur Financier Eric Soyer est revenu sur nos derniers jalons créateurs de valeur pour @ArnaudBives @Boursier_com :

✅ Xervyteg® (MaaT013) : Dossier d’AMM en cours d’évaluation par l’EMA. Si approuvé, il s’agira de la première thérapie issue du microbiote approuvée en Europe, avec une commercialisation potentielle prévue dès le second semestre 2026.
✅ Développements cliniques : Poursuite de l’étude de Phase 2b PHOEBUS (MaaT033), et des programmes exploratoires en immuno-oncologie et le développement préclinique de MaaT034.
✅ Partenariats et financement : accord exclusif avec Clinigen pour Xervyteg® en Europe, financement de la BEI.

👉 Lire l’interview complète : https://t.co/dO1x36TX9H

[MTIG @MTIG_News]

MTIG is a coalition of companies leading the development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes and reduce health care costs. Learn more about our work here: https://t.co/OBxLhh5gw3

[Jake P. Taylor-King @wildtypehuman]

To all of the folk saying we need deep learning for RNA-seq prediction...

[MaaT Pharma @MaaT_Pharma]

📄 [Press release] – MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (@EIB ) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

This structured debt financing will support the advancement of our late-stage clinical assets, including:
- Xervyteg®, currently under review by the EMA
- MaaT033, now in Phase 2b clinical evaluation
This funding is a strong vote of confidence in our innovative work in hemato-oncology and marks a new step in our multi-sourcing financing strategy and reinforces the EIB’s commitment to supporting biotech companies with cutting-edge expertise in areas with high unmet medical needs.

👉 For more information, read the full press release: https://t.co/xiLaIIu3s1

#HematoOncology #EIB #Biotech #ClinicalDevelopment
#MicrobiomeTherapies #Financing #EMA #Microbiotherapy

[Seventure Partners @SeventureP]

[Health for Life Capital portfolio] 🙌@MaaT_Pharma lands €37.5M from @EIB to accelerate #cancer therapy development. Xervyteg® under EMA review, MaaT033 in Phase 2b trials. Full press release 👉 https://t.co/4pSCJUpFcT #Microbiome 🦠

[Emmanuel G Prestat @ManuFrenchy]

Did you see that? It’s quite big! 👇
So happy to see our first product finding a way to reach more and more patients. What an achievement!

[MTIG @MTIG_News]

.@MaaT_Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe https://t.co/fi7Vdrz8eu

[MTIG @MTIG_News]

.@MaaT_Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe https://t.co/fi7Vdrz8eu

[MaaT Pharma @MaaT_Pharma]

🦠 [#WMD2025] - How Microbiome Research Is Transforming Medicine?
To mark World Microbiome Day 2025, we spoke with Dr. Joël Doré, Research Director at INRAE, Scientific advisor, co-founder of MaaT Pharma, and one of the world’s leading microbiome experts.

Dr. Doré describes the gut microbiome as a true “control hub for health” — influencing immunity, inflammation, and even treatment outcomes in cancer.

👉 Read the full interview: https://t.co/IVqJvv4qDr

@dorejoel
#WorldMicrobiomeDay #GutHealth #Immunity #MicrobiomeResearch #HealthRevolution

[MaaT Pharma @MaaT_Pharma]

💬 “These data clearly confirm the efficacy of MaaT013 in aGvHD,” said Prof. Mohty @Mohty_EBMT at #EHA2025 during oral presentation.

With a favorable safety profile, Xervyteg® (MaaT013) our full-ecosystem microbiotherapy is showing real promise in a high unmet need and we are proud to bring solutions to patients, to transplant physicians, and to the entire hematology community.

📽️ Watch the recap below .@TheIACH
#MaaT013 #Microbiome #aGvHD #Biotech
@EHA_Hematology #hematology #GVHD

[MaaT Pharma @MaaT_Pharma]

EN- 📅 [#Event] – Guilhaume Debroas, Ph.D, Head of Investor Relations at MaaT Pharma, will participate in the MID & SMALL CAPS 2025 Conference by @PortzamparcBNPP, taking place on June 18-19 in Paris.
📍 Join us at the Étoile Business Center (21-25 Rue Balzac, 75008 Paris), for this event dedicated to listed small and mid-cap companies and the investor community.

FR- 📅 [#Événement] – Guilhaume Debroas, Ph.D, Head of Investor Relations chez MaaT Pharma, participera à la conférence MID & SMALL CAPS 2025 organisée par @PortzamparcBNPP, qui se tiendra les 18 et 19 juin à Paris.
📍 Rejoignez-nous à l’Étoile Business Center (21-25 Rue Balzac, 75008 Paris), pour cet événement dédié aux sociétés cotées de petite et moyenne capitalisation, et à l’ensemble des acteurs de la communauté financière.

#InvestorRelations #Biotech #LifeSciences #SmallCaps #MidCaps #Finance #Innovation

[Emmanuel G Prestat @ManuFrenchy]

@merenbey Good to see @DelmontTom ´s face ! I hope I’m not responsible for the “I don’t code” thing, remembering him asking how was my “python des neiges”…

[A. Murat Eren (Meren) @merenbey]

The best opening slide doesn't exi...

[MaaT Pharma @MaaT_Pharma]

📄[Press release] – MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 for the treatment of acute Graft-versus-Host Disease🩸

Read the press release: https://t.co/FT8grVUcKM

#BloodCancer #Cancer #EMA #aGvHD #Pediatric #EMA #Milestone

[MaaT Pharma @MaaT_Pharma]

📄[Communiqué de presse] – MaaT Pharma reçoit un avis positif du Comité Pédiatrique de l'EMA pour le plan d'investigation pédiatrique de MaaT013 dans le traitement de la maladie aiguë du greffon contre l’hôte🩸
Voir le communiqué de presse : https://t.co/rBSq9T3brb

#EMA #MaaT013 #EMA #aGvH #Pédiatrique